GlassScriptPhysician profile
Hemen Shah
NPI 1821002601
$2,652.25
in general payments reported to CMS, 2019-2025
39 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2022: $16.85 · 2023: $537 · 2024: $823 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $494.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $243.72 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $224.31 | 2023-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $184.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $121.08 | 2023-2025 | Ubrelvy, Synthroid, Qulipta |
| Medtronic, INC. | $93.08 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Pfizer INC. | $91.56 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.67 | 2024-2025 | Jardiance |
| Tactile Systems Technology INC | $76.50 | 2019-2025 | Nimbl, Flexitouch Plus |
| Antares Pharma, INC. | $72.43 | 2024-2025 | Xyosted |
| Radius Health, INC. | $68.86 | 2024-2025 | Tymlos |
| Abbott Laboratories | $66.01 | 2023-2025 | Freestyle Libre 3 |
| Tosoh Bioscience, INC. | $62.00 | 2019 | |
| Ibsa Pharma INC. | $61.18 | 2023 | Tirosint, Licart |
| Astrazeneca Pharmaceuticals LP | $57.08 | 2024-2025 | Airsupra, Breztri, Farxiga |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $52.16 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $46.75 | 2023-2024 | |
| Lundbeck LLC | $46.58 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2025 | Eliquis |
| Dexcom, INC. | $36.76 | 2023-2024 | Dexcom G6 Transmitter |
| Embecta Corp. | $36.27 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alnylam Pharmaceuticals INC. | $34.99 | 2025 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $33.50 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.51 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $30.94 | 2025 | |
| Amneal Pharmaceuticals LLC | $29.52 | 2025 | Unithroid |
| Chiesi USA, INC. | $26.06 | 2025 | Mycapssa |
| Merck Sharp & Dohme LLC | $25.40 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Recordati_rare_diseases_inc. | $19.70 | 2024 | Signifor Lar, Isturisa |
| Beta Bionics, INC. | $19.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Idorsia Pharmaceuticals US INC | $18.02 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.89 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $16.87 | 2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $16.85 | 2022 | |
| Esperion Therapeutics, INC. | $15.70 | 2025 | Nexletol |
| Seqirus USA INC | $15.41 | 2025 | Fluad, Flucelvax |
| Biotronik Nro, INC. | $14.73 | 2024 | Prospera |
| Insulet Corporation | $13.48 | 2024 | Omnipod |
| Nevro Corp. | $12.90 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemen Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.